Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal
Pharma giant GSK PLC said Tuesday that it has agreed to acquire cancer therapy specialist Nuvalent Inc. for $10.6 billion as it seeks to accelerate its "rapid expansion" into the oncology...To view the full article, register now.
Already a subscriber? Click here to view full article